The Babak Lab posted on Linkedin:
Clinical Mondays: Nivolumab in first-line Hodgkin lymphoma (SWOG S1826)
The FDA has approved nivolumab in combination with chemotherapy for previously untreated classical Hodgkin lymphoma, based on results from the SWOG S1826 trial.
Key Focus
The study evaluates the use of a PD-1 inhibitor as part of first-line therapy, rather than in relapsed or refractory disease.
Key Insights
• Nivolumab + chemotherapy showed improved outcomes compared to standard treatment.
• The regimen demonstrated a favorable safety profile.
• The results support earlier integration of immunotherapy in Hodgkin lymphoma.
Conclusion
This approval represents an expanded indication of an already established drug, moving nivolumab into the frontline setting and potentially redefining standard of care.”
Other articles from The Babak Lab on OncoDaily